- News & Events
Mapi is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients (“APIs”), formulations and life cycle management (“LCM”) products that target large markets. We are currently developing two LCM products for the treatment of multiple sclerosis (“MS”) and neuropathic pain. LCM products are new forms of marketed drugs that may offer advantages over existing formulations, such as improved patient compliance and reduced side effects, and allow extended patent and regulatory exclusivity of a marketed drug due to different formulations of product components, for example through depot or extended release formulations. Our LCM products seek to add value to products that are expected to go off-patent by integrating off-patent APIs with our formulations, resulting in a new final combination that is believed to be patentable. We are also developing a portfolio of 13 complex APIs, seven of which we intend to develop formulations for, a generic version of Risperdal® Consta®, Johnson & Johnson’s long acting injection of Risperidone for the treatment of schizophrenia and bipolar disorder and a new chemical entity, a novel pentapolymer developed for treating autoimmune diseases such as MS.
Mapi was founded in 2008.
Mapi is headquartered at the Weizmann Science Park in Ness Ziona, Israel.
Meet our Management Team.
Mapi has a worldwide team of 32 employees.
Mapi is incorporated in the State of Israel.
Mapi’s common shares will be traded on the NASDAQ Capital Market under the symbol “MAPI”.
All events will be reported on this site. Please see the event page for more information. You can also sign up for e-mail alerts.
If you would like to purchase shares in Mapi, please contact your broker.
We do not offer a direct stock purchase or dividend reinvestment program.
Mapi does not anticipate paying any cash dividends in the foreseeable future.
Our fiscal year follows the calendar year, with the last day of our fiscal year occurring on December 31. The Company’s quarterly periods conclude on March 31, June 30, September 30, and December 31.
The transfer agent and registrar for our ordinary shares is VStock Transfer, LLC.
You can go to the official SEC site or you can follow this link to our page.
KPMG Somekh Chaikin
VP Corporate Development
Please submit your question via contact us